AI-extracted from the 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
ADMA's Q2 revenue grew just 2.0% to $124.4M as 23.5% ASCENIV growth was nearly offset by a 48.5% BIVIGAM decline from competitive IVIG pricing pressure, while gross margin expanded sharply to 69.4% from 55.1%.
Biggest Revenue Drivers
ADMA BioManufacturing$123.6M+1.4% YoY
Plasma Collection Centers$0.7M+100.0% YoY
Biggest Revenue Drivers
Total revenue: $124.4M+2.0% YoY
ADMA BioManufacturing$123.6M+1.4% YoY
Within ADMA BioManufacturing
ASCENIV$102.9M+23.5% YoY
Reflects continued growth in market acceptance of the product
BIVIGAM$19.4M-48.5% YoY
Reflects continued competitive pressures in the standard immune globulin market
Plasma Collection Centers$0.7M+100.0% YoY
Largest Expense Items
Selling, general and administrative$26.7M+20.4% YoY
Higher employee-related costs, increased software maintenance costs, and higher professional and legal fees tied to ongoing litigation and strategic initiatives
Research and development$6.0M+383% YoY
Ramp-up of clinical development and trial activities related to the SG-001 development project
Plasma center operating expenses$1.0M-10.9% YoY
Decrease primarily due to the sale of three plasma centers in the first quarter of 2026
Margins: Gross margin rose to 69.4% from 55.1% a year ago, driven by favorable product mix (higher ASCENIV, lower BIVIGAM) and margin benefits from the FDA-approved yield enhancement manufacturing process.
Watch Items from the Filing
Three customers represented approximately 76% of Q2 2026 consolidated revenues; two customers (BioCare and CuraScript) represented approximately 81% of accounts receivable at quarter-end.
On July 10, 2026 a putative securities class action (Mazzarino v. ADMA) was filed against the company and certain officers alleging Exchange Act violations; damages unspecified and no accrual recorded.
New FDA-approved IVIG products entering the market with aggressive pricing tactics (extended payment terms, rebates, discounts) drove the 48.5% BIVIGAM revenue decline and elevated industry-wide inventory.
Company borrowed $125.0M under its JPM Revolving Facility to fund an accelerated share repurchase, leaving $198.1M in variable-rate debt outstanding as of June 30, 2026.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Tade Brad L.CFO and TreasurerShares withheld for tax or exercise price · Feb 19, 2026
Salas Eduardo ReneReporting ownerGrant or award · Feb 9, 2026
Finger Alison CecilyReporting ownerGrant or award · Feb 9, 2026
Kwon YoungReporting ownerGrant or award · Feb 9, 2026
About ADMA BIOLOGICS, INC. (ADMA): stock profile, AI score and financials
ADMA BIOLOGICS, INC. (ADMA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ADMA at 69.6/100 on a composite quality score built from its SEC filings, placing it at rank #245 of 2,925 stocks — the top 10% of the AI-ranked universe. ADMA scores in the top quartile across balance sheet strength (98.0), profitability (86.6), revenue growth (84.5). Areas of concern include institutional flow (11.7) and revenue scale (37.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 27.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), ADMA BIOLOGICS, INC. reports quarterly revenue of $124.4M, net income of $37.8M, an operating margin of 42.2%. Top institutional holders of ADMA by reported 13-F value include BlackRock, STATE STREET, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. ADMA trades on the Nasdaq exchange and files with the SEC under CIK 1368514. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ADMA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ADMA BIOLOGICS, INC. directly from SEC EDGAR.